Charge Enterprises, Inc. (NASDAQ: CRGE) Interview: Andrew Fox, CEO
Globally renowned serial entrepreneur with over two decades of experience in executing disruptive approaches to a wide range of industries including media, transportation, real estate, insurance, and consumer staples. Founded numerous companies with multiple successful exits, including Track Entertainment, WantTickets and Way Communications. Angel
investor in over 25 leading startups
OKYO Pharma Announces Activation of First Clinical Trial Site in the U.S. for the Phase 2 Trial Evaluating OK-101 for the Treatment of Dry Eye Disease
OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease to address the significant unmet need in this multi-billion-dollar market, today announces the activation of the first clinical trial site in the ...
Charge Enterprises Reports Record Infrastructure Backlog Surpassing $100 Million and Reaffirms Growth Strategy
Charge Enterprises, Inc. (Nasdaq: CRGE) today reported record backlog after the close of the first quarter 2023 and reaffirmed its commitment to pursuing growth within the EV charging infrastructure sector.
Charge Enterprises Sets Date for 2023 First Quarter Financial Results Webcast
Charge Enterprises, Inc. (Nasdaq: CRGE) plans to host a public results webcast on May 10, 2023, during which Charge’s executive management will review and discuss the Company’s 2023 first quarter financial results.
Tiziana Life Sciences: A Biotech Microcap Revolutionizing Neurological Disorder Treatment with the Only Intranasal Fully Human anti-CD3 Monoclonal Antibody in Clinical Development
Tiziana Life Sciences Ltd is a biotechnology company focused on discovering and developing molecules for the treatment of human diseases in oncology and immunology.
NanoViricides Signs a License Agreement That Includes Clinical Evaluation of Its COVID-19 Drug Candidates
NanoViricides, Inc. (NYSE Amer.: NNVC) a global leader in nanomedicines against viruses, announced today that it has executed a License Agreement with Karveer Meditech Pvt. Ltd., Kolhapur, India (“Karveer”).
SUNSHINE BIOPHARMA REPORTS FULL YEAR ENDED DECEMBER 31, 2022 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced reporting of operating results for the fiscal year ended December 31, 2022 and recent highlights.